ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vorapaxar. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2014-11-01

PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease.

Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA.

J Thromb Thrombolysis · randomized controlled trial; journal article · DOI 10.1007/s11239-014-1075-4

Bibliografisk träff 2014-10-01

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

Chen X, Kosoglou T, Statkevich P, Kumar B, Li J, Dockendorf MF, Wang G, Lowe RS, Jiang J, Liu H, Wang Z, Cutler DL, Hu P.

Int J Clin Pharmacol Ther · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.5414/cp202121

Bibliografisk träff 2014-07-10

Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.

White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW.

J Am Heart Assoc · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1161/jaha.114.001032

Bibliografisk träff 2014-07-04

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).

Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW.

Am Heart J · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ahj.2014.06.017

Bibliografisk träff 2014-07-01

Vorapaxar: first global approval.

Poole RM, Elkinson S.

Drugs · review; journal article · DOI 10.1007/s40265-014-0252-2

Bibliografisk träff 2014-06-18

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).

Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ.

Am J Cardiol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.amjcard.2014.05.054

Bibliografisk träff 2014-04-21

PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.

Judge HM, Jennings LK, Moliterno DJ, Hord E, Ecob R, Tricoci P, Rorick T, Kotha J, Storey RF.

Platelets · research support, non-u.s. gov't; journal article · DOI 10.3109/09537104.2014.902924

Bibliografisk träff 2014-04-03

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Cho JR, Rollini F, Franchi F, Ferrante E, Angiolillo DJ.

Vasc Health Risk Manag · review-article; review; journal article · DOI 10.2147/vhrm.s36045

Bibliografisk träff 2014-03-13

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.

Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, Moliterno DJ, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW.

Eur Heart J Acute Cardiovasc Care · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1177/2048872614527838

Bibliografisk träff 2014-01-09

Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.

Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK.

Thromb Haemost · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1160/th13-07-0624

Bibliografisk träff 2013-12-25

Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).

Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA.

Am J Cardiol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.amjcard.2013.11.052

Bibliografisk träff 2013-11-21

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW.

J Am Coll Cardiol · comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jacc.2013.10.048

Bibliografisk träff 2013-03-25

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.

Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA, Mahaffey KW.

Eur Heart J · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/eurheartj/eht104

Bibliografisk träff 2013-03-15

Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.

Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA.

Circulation · multicenter study; randomized controlled trial; journal article · DOI 10.1161/circulationaha.112.000679

Bibliografisk träff 2013-02-20

The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.

Kosoglou T, Statkevich P, Kumar B, Xuan F, Schiller JE, Johnson-Levonas AO, Young S, Cutler DL.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/jcph.20

Bibliografisk träff 2013-02-08

Efficacy and safety of vorapaxar in patients with prior ischemic stroke.

Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E, Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators.

Stroke · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1161/strokeaha.111.000433